Hwanhee Hong
YOU?
Author Swipe
View article: Large Language Models to Estimate CGI-S From Clinical Notes as a Measure of Depression Severity (Preprint)
Large Language Models to Estimate CGI-S From Clinical Notes as a Measure of Depression Severity (Preprint) Open
BACKGROUND Real-world psychiatric care is marked by wide heterogeneity in clinical presentations and outcomes, underscoring the need for systematic approaches to outcome measurement. The Clinical Global Impression–Severity (CGI-S) scale i…
View article: 217 Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: the 52-Week Phase 3 INTEGUMENT-OLE Trial in ≥2-year-olds
217 Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: the 52-Week Phase 3 INTEGUMENT-OLE Trial in ≥2-year-olds Open
View article: Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials Open
View article: Precision Mental Health: Predicting Heterogeneous Treatment Effects for Depression through Data Integration
Precision Mental Health: Predicting Heterogeneous Treatment Effects for Depression through Data Integration Open
When treating depression, clinicians are interested in determining the optimal treatment for a given patient, which is challenging given the amount of treatments available. To advance individualized treatment allocation, integrating data a…
View article: Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks Open
Measure Up 1 (NCT03569293; https://clinicaltrials.gov/study/NCT03569293 ), Measure Up 2 (NCT03607422; https://clinicaltrials.gov/study/NCT03607422 ), and AD Up (NCT03568318; https://clinicaltrials.gov/study/NCT03568318 ).
View article: Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16
Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16 Open
ClinicalTrials.gov identifier, NCT03526861 (ECZTRA 6); study start date: 19 June 2018; primary completion date: 15 April 2020; study completion date: 16 March 2021. A Graphical Abstract is available for this article.
View article: Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis
Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis Open
LEBRI improved EASI HN subscore and HN EASI clinical signs of erythema and facial dermatitis at Week 16. During the PBO-controlled period, an increased reporting of HN and facial erythema as TEAE was not observed in the LEBRI group and HN …
View article: 0462 Efficacy and tolerability of roflumilast cream 0.15% for atopic dermatitis: Pooled subgroup analysis of patients with face/eyelid involvement from phase 3 INTEGUMENT-1/2 trials
0462 Efficacy and tolerability of roflumilast cream 0.15% for atopic dermatitis: Pooled subgroup analysis of patients with face/eyelid involvement from phase 3 INTEGUMENT-1/2 trials Open
View article: P104 Lebrikizumab improves quality of life in patients with moderate-to-severe atopic dermatitis inadequately controlled or ineligible for ciclosporin (ADvantage study)
P104 Lebrikizumab improves quality of life in patients with moderate-to-severe atopic dermatitis inadequately controlled or ineligible for ciclosporin (ADvantage study) Open
Ciclosporin A (CsA) is indicated for the treatment of severe atopic dermatitis (AD), but its efficacy may not be optimal and its safety limits longer-term use. Lebrikizumab (LEB) is a high-affinity anti-interleukin-13 monoclonal antibody. …
View article: P105 Lebrikizumab improves quality of life and wellbeing of patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin: German extension results (week 76) of the ADvantage study
P105 Lebrikizumab improves quality of life and wellbeing of patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin: German extension results (week 76) of the ADvantage study Open
Lebrikizumab (LEB), a high-affinity anti-interleukin-13 monoclonal antibody, showed efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD). Ciclosporin A (CsA) is indicated for severe AD, but its efficacy may not be…
View article: Canadian Consensus Guidelines for the Management of Vitiligo
Canadian Consensus Guidelines for the Management of Vitiligo Open
View article: Ultrafast electron transport in 2D van der Waals heterostructures Bi<sub>2</sub>Te<sub>3</sub>/Fe<sub>4</sub>GeTe<sub>2</sub> probed by terahertz spectroscopy
Ultrafast electron transport in 2D van der Waals heterostructures Bi<sub>2</sub>Te<sub>3</sub>/Fe<sub>4</sub>GeTe<sub>2</sub> probed by terahertz spectroscopy Open
The research on two-dimensional (2D) magnetic materials and their heterostructures is crucial in fields like spintronics, materials science, and condensed matter physics. This study uses terahertz (THz) time-domain spectroscopy to investig…
View article: Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years Open
View article: Integrating Randomized Controlled Trial and External Control Data Using Balancing Weights: A Comparison of Estimands and Estimators
Integrating Randomized Controlled Trial and External Control Data Using Balancing Weights: A Comparison of Estimands and Estimators Open
Randomized controlled trials (RCTs) face inherent limitations, such as ethical or resource constraints, which lead to a limited number of study participants. To address these limitations, recent research endeavors have sought to incorporat…
View article: A Bayesian Re-analysis of the Steroids to Reduce Systemic Inflammation after Infant Heart Surgery (STRESS) Trial
A Bayesian Re-analysis of the Steroids to Reduce Systemic Inflammation after Infant Heart Surgery (STRESS) Trial Open
Background Prophylactic steroids are often used to reduce the systemic inflammatory response to cardiopulmonary bypass in infants undergoing heart surgery. The STRESS trial found that the likelihood of a worse outcome did not differ betwee…
View article: Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis Open
Background Approved tralokinumab maintenance dosing regimens for treatment of moderate-to-severe atopic dermatitis (AD) include 300 mg every 2 weeks (Q2W) and every 4 weeks (Q4W). Clinicians may consider tralokinumab Q4W for patients whose…
View article: Bayesian hierarchical models with calibrated mixtures of g-priors for assessing treatment effect moderation in meta-analysis
Bayesian hierarchical models with calibrated mixtures of g-priors for assessing treatment effect moderation in meta-analysis Open
Assessing treatment effect moderation is critical in biomedical research and many other fields, as it guides personalized intervention strategies to improve participant's outcomes. Individual participant-level data meta-analysis (IPD-MA) o…
View article: Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up) Open
Background Atopic dermatitis (AD) is a chronic skin disease characterized by intense itch and eczematous skin lesions. Some patients with AD continue to experience flares and substantial clinical burden, despite ongoing systemic treatment.…
View article: 7718 Dysregulated BCAA catabolism and insulin secretory response in the early stages of insulin resistance in mature adolescents
7718 Dysregulated BCAA catabolism and insulin secretory response in the early stages of insulin resistance in mature adolescents Open
Disclosure: A. Basin: None. Q. Wang: None. H. Hong: None. O. Ilkayeva: None. M. Muehlbauer: None. D. Hsia: None. D.A. D'Alessio: None. C.B. Newgard: None. M. Freemark: None. P. Gumus Balikcioglu: None. Objective: We recently showed that su…
View article: Biomarker-Guided Adaptive Enrichment Design with Threshold Detection for Clinical Trials with Time-to-Event Outcome
Biomarker-Guided Adaptive Enrichment Design with Threshold Detection for Clinical Trials with Time-to-Event Outcome Open
Biomarker-guided designs are increasingly used to evaluate personalized treatments based on patients' biomarker status in Phase II and III clinical trials. With adaptive enrichment, these designs can improve the efficiency of evaluating th…
View article: Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials Open
Lebrikizumab treatment demonstrated efficacy in improving the signs and symptoms of AD in adolescent patients, consistent with the ADvocate and ADhere overall population results.
View article: Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial Open
Background Dysregulated interleukin (IL)-17/IL-23 signalling contributes to psoriasis pathogenesis. Cedirogant is an inverse agonist of nuclear receptor ROR-gamma isoform 2 (RORyt), a key transcription factor responsible for IL-17 synthesi…
View article: 901 Cross-sectional analysis of lupus erythematosus and dermatomyositis stress and cardiovascular health (LEADS-CV) data reveals ideal cardiovascular health is rare in affected youth
901 Cross-sectional analysis of lupus erythematosus and dermatomyositis stress and cardiovascular health (LEADS-CV) data reveals ideal cardiovascular health is rare in affected youth Open
Funding This study was supported by the Rheumatology Research Foundation Investigator Award (PI: Ardalan). Disclosures KA – Cure JM Foundation (support for clinical trial design with ReveraGen BioPharma) LES – Bristol Myers Squibb (researc…
View article: Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis Open
View article: Inference of treatment effect and its regional modifiers using restricted mean survival time in multi-regional clinical trials
Inference of treatment effect and its regional modifiers using restricted mean survival time in multi-regional clinical trials Open
Multi-regional clinical trials (MRCTs) play an increasingly crucial role in global pharmaceutical development by expediting data gathering and regulatory approval across diverse patient populations. However, differences in recruitment prac…
View article: Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial Open
View article: Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials
Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials Open
Introduction: Roflumilast cream 0.15% is a highly selective phosphodiesterase 4 inhibitor under investigation as a once-daily, nonsteroidal treatment for atopic dermatitis (AD). Pooled safety and efficacy results of two Phase 3 clinical tr…
View article: Optimizing warfarin dosing for patients with atrial fibrillation using machine learning
Optimizing warfarin dosing for patients with atrial fibrillation using machine learning Open
View article: Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor) Open
View article: Comparison of methods that combine multiple randomized trials to estimate heterogeneous treatment effects
Comparison of methods that combine multiple randomized trials to estimate heterogeneous treatment effects Open
Individualized treatment decisions can improve health outcomes, but using data to make these decisions in a reliable, precise, and generalizable way is challenging with a single dataset. Leveraging multiple randomized controlled trials all…